Tags

Type your tag names separated by a space and hit enter

Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer.
Curr Opin Oncol 2014; 26(1):31-5CO

Abstract

PURPOSE OF REVIEW

The incidence of well differentiated thyroid cancer (WDTC) is increasing in the US population and is now a major public health concern. Although surgery is the mainstay of treatment, radioactive iodine (RAI) is routinely used for adjuvant therapy, remnant ablation, and for the treatment of metastatic disease. Despite excellent prognosis and stable mortality rates, the use of RAI is increasing in many low and intermediate risk WDTC patients without clear indication that it changes the outcome. As a result, the current treatment paradigm has shifted towards a risk-stratified approach.

RECENT FINDINGS

Although there is widespread acceptance that RAI improves overall and recurrence-free survival in patients with metastatic disease, controversy remains regarding radioactive remnant ablation use in low and intermediate risk patients. Additional studies have shown that reduced doses of RAI can provide similar rates of remnant ablation and adjuvant therapy in low and intermediate risk patients without adversely affecting the recurrence rates and mortality.

SUMMARY

Recent studies suggest potential new paradigms in radioactive remnant ablation dosing and indications for use. Risk stratification is important in determining the proper use and dosing of RAI.

Authors+Show Affiliations

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24225414

Citation

Bohinc, Brittany N., and Jennifer M. Perkins. "Appropriate Dosing of Adjuvant Radioactive Iodine for Differentiated Thyroid Cancer." Current Opinion in Oncology, vol. 26, no. 1, 2014, pp. 31-5.
Bohinc BN, Perkins JM. Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer. Curr Opin Oncol. 2014;26(1):31-5.
Bohinc, B. N., & Perkins, J. M. (2014). Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer. Current Opinion in Oncology, 26(1), pp. 31-5. doi:10.1097/CCO.0000000000000039.
Bohinc BN, Perkins JM. Appropriate Dosing of Adjuvant Radioactive Iodine for Differentiated Thyroid Cancer. Curr Opin Oncol. 2014;26(1):31-5. PubMed PMID: 24225414.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer. AU - Bohinc,Brittany N, AU - Perkins,Jennifer M, PY - 2013/11/15/entrez PY - 2013/11/15/pubmed PY - 2014/7/25/medline SP - 31 EP - 5 JF - Current opinion in oncology JO - Curr Opin Oncol VL - 26 IS - 1 N2 - PURPOSE OF REVIEW: The incidence of well differentiated thyroid cancer (WDTC) is increasing in the US population and is now a major public health concern. Although surgery is the mainstay of treatment, radioactive iodine (RAI) is routinely used for adjuvant therapy, remnant ablation, and for the treatment of metastatic disease. Despite excellent prognosis and stable mortality rates, the use of RAI is increasing in many low and intermediate risk WDTC patients without clear indication that it changes the outcome. As a result, the current treatment paradigm has shifted towards a risk-stratified approach. RECENT FINDINGS: Although there is widespread acceptance that RAI improves overall and recurrence-free survival in patients with metastatic disease, controversy remains regarding radioactive remnant ablation use in low and intermediate risk patients. Additional studies have shown that reduced doses of RAI can provide similar rates of remnant ablation and adjuvant therapy in low and intermediate risk patients without adversely affecting the recurrence rates and mortality. SUMMARY: Recent studies suggest potential new paradigms in radioactive remnant ablation dosing and indications for use. Risk stratification is important in determining the proper use and dosing of RAI. SN - 1531-703X UR - https://www.unboundmedicine.com/medline/citation/24225414/Appropriate_dosing_of_adjuvant_radioactive_iodine_for_differentiated_thyroid_cancer_ L2 - http://dx.doi.org/10.1097/CCO.0000000000000039 DB - PRIME DP - Unbound Medicine ER -